The MS Trust is dismayed by NICE's recommendation. We do not believe it is in the best interests of people with MS or the NHS.
Medday, the company developing high dose biotin for progressive MS, has told the European Medicines Agency that it wishes to withdraw its licence application.
The European Medicines Agency recommends licensing for ocrelizumab (Ocrevus) for treating active relapsing and early primary progressive MS.
NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately.
Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales.
Ibudilast slowed down the loss of brain volume in primary and secondary progressive MS by almost one half compared to placebo according to results presented at ECTRIMS 2017.
Results of a small study suggest that clemastine, a drug used to treat allergies, may repair damage to myelin in the optic nerve of people with MS.
The MS Trust and NHS Lanarkshire are delighted to announce that they have worked together to recruit two new MS specialist nurses, plus a part-time neurology nurse, to support the 1,200 people living with MS in Lanarkshire. The new nurses will begin work later in September.
The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad) for the treatment of adults with highly active relapsing multiple sclerosis.
This is an exciting opportunity to provide high quality care for people with MS across Lanarkshire, and receive support from the MS Trust to build an efficient, effective, equitable and sustainable service.